secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0000950170-24-038414
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics posts Q4 net loss $12.4M; NDA resubmission planned early Q2 2024
--------------------------------------------------------------------------------

- Net loss of $12.4M for Q4 2023; full year 2023 net loss $38.4M; non-GAAP net loss $10.7M (Q4) and $43.8M (FY).
- Cash, equivalents & short-term investments $23.9M at Dec 31; raised $7.1M post-period via ATM, extending cash runway into 2025.
- NDA resubmission for oral sulopenem in uUTIs on track for early Q2 2024; FDA action expected early Q4 2024 under 6-month review.
- Engaged financial advisor to explore strategic alternatives including a sale or license of sulopenem rights.
- R&D expenses rose to $9.7M (Q4) and $40.0M (FY) driven by the REASSURE trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/0000950170-24-038414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/itrm-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer